{"id":5128,"date":"2025-10-24T13:02:40","date_gmt":"2025-10-24T11:02:40","guid":{"rendered":"https:\/\/avextra.com\/?p=5128"},"modified":"2025-10-24T13:13:13","modified_gmt":"2025-10-24T11:13:13","slug":"avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien","status":"publish","type":"post","link":"https:\/\/avextra.com\/it\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/","title":{"rendered":"Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative"},"content":{"rendered":"<h4 class=\"wp-block-heading\"><strong><strong>Arruolato il primo paziente nello studio randomizzato, controllato con placebo<\/strong><\/strong><\/h4>\n\n\n\n<p><strong><strong><strong>Bensheim, 24. ottobre 2025<\/strong><\/strong> \u2013<\/strong>&nbsp;Le malattie neurodegenerative rappresentano una delle pi\u00f9 grandi sfide del nostro tempo. Solo in Germania vivono oggi circa 1,8 milioni di persone affette da demenza, una cifra destinata a raggiungere i 2,7 milioni entro il 2050. L\u2019aumento dell\u2019aspettativa di vita, insieme alla crescita del numero di pazienti, comporta un impatto sempre pi\u00f9 significativo per le persone colpite, le loro famiglie e i sistemi sanitari nazionali.<\/p>\n\n\n\n<p>Nonostante i progressi della ricerca, mancano ancora percorsi terapeutici realmente efficaci, capaci di offrire un sollievo sintomatico e di migliorare in modo sostenibile la qualit\u00e0 della vita dei pazienti.<\/p>\n\n\n\n<p>In questo scenario nasce l\u2019esigenza di sviluppare opzioni terapeutiche aggiuntive basate su solide evidenze cliniche. La <strong>cannabis medica,&nbsp;<\/strong>in particolare nella forma di <strong>estratto di fitocomplesso completo (full extract),&nbsp;<\/strong>rappresenta una promettente area di indagine per le sue potenzialit\u00e0 nel modulare i sistemi neurofisiologici coinvolti nei processi degenerativi.<\/p>\n\n\n\n<p>Con questo obiettivo prende avvio in Italia lo <strong>studio NEUROBIS,&nbsp;<\/strong>un <strong>trial clinico di fase II,&nbsp;<\/strong>randomizzato, in doppio cieco e controllato con placebo, volto a valutare l\u2019efficacia in termini di qualit\u00e0 della vita e la sicurezza dei farmaci a base di cannabis (CbM) nelle malattie neurodegenerative.<\/p>\n\n\n\n<p><strong>Lo studio, della durata di 36 mesi \u00e8 autorizzato e finanziato dal Ministero della Salute Italiano (Ricerca Finalizzata 2022) e prevede il coinvolgimento di 180 pazienti affetti rispettivamente da Sclerosi Laterale Amiotrofica, Morbo di Parkinson e Malattia di Alzheimer. Il primo paziente \u00e8 gi\u00e0 stato arruolato,<\/strong> segnando una tappa fondamentale nella ricerca clinica sull\u2019impiego dei CbM come trattamento di supporto.<\/p>\n\n\n\n<p><strong>La sperimentazione \u00e8 guidata dalla Professoressa Letizia Mazzini,&nbsp;<\/strong>neurologa e ricercatrice di fama internazionale con oltre 30 anni di esperienza nello studio delle malattie neurodegenerative, direttrice del Centro SLA di Novara e tra i principali esperti italiani di malattie del motoneurone.<\/p>\n\n\n\n<p><em>\u201cSiamo orgogliosi di avviare in Italia questo studio clinico pionieristico,\u201d <\/em>- afferma la professoressa Mazzini -<em> \u201cGrazie alla collaborazione con Avextra, uniamo competenza clinica e innovazione per esplorare in modo rigoroso il potenziale terapeutico della cannabis medicinale come opzione aggiuntiva per i pazienti affetti da patologie neurodegenerative. Il nostro obiettivo \u00e8 generare dati scientifici di alta qualit\u00e0 che possano tradursi in benefici clinici reali.\u201d<\/em><\/p>\n\n\n\n<p><strong>Bernhard Babel&nbsp;<\/strong>CEO di <strong>Avextra&nbsp;<\/strong>sottolinea il valore strategico di questa iniziativa di ricerca: <em>\u201cL\u2019avvio dello studio NEUROBIS rappresenta un passo decisivo nel nostro programma di ricerca clinica. Grazie al nostro <strong>estratto di fitocomplesso completo di cannabis (full extract),&nbsp;<\/strong>sviluppato secondo i pi\u00f9 elevati standard di qualit\u00e0 e uniformit\u00e0, perseguiamo l\u2019obiettivo di migliorare la qualit\u00e0 della vita dei pazienti e di offrire nuove prospettive terapeutiche fondate su evidenze solide e verificabili.\u201d<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><strong>Informazioni su Avextra<\/strong><\/strong><\/h2>\n\n\n\n<p>Avextra \u00e8 un\u2019azienda biotecnologica con sede in Assia (Germania), specializzata nello sviluppo di farmaci a base di cannabis. Con un forte impegno nella ricerca clinica, l\u2019azienda conduce sei studi pionieristici in Germania e in Europa, con l\u2019obiettivo di ottenere l\u2019autorizzazione all\u2019immissione in commercio e garantire ai pazienti un accesso sostenibile a terapie cannabinoidi nei settori del dolore, delle cure palliative e delle patologie neurodegenerative.<\/p>\n\n\n\n<p>Per ulteriori informazioni: <a href=\"https:\/\/avextra.com\/it\/\">www.avextra.com<\/a> | <a href=\"http:\/\/LinkedIn.com\/company\/avextra-ag\/\">LinkedIn.<\/a><\/p>\n\n\n\n<p><strong><strong>Contatti stampa<\/strong><\/strong><\/p>\n\n\n\n<p>Per domande da parte dei media o per organizzare un'intervista, contattare:<br>E-Mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href=\"mailto:press@avextra.com\">press@avextra.com<\/a><br>Phone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +49 30 408174037&nbsp;<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-primary-color has-text-color has-link-color wp-elements-809a0976a752b732a6750d93ff9c5cba\"><strong><em><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/10\/24\/3172636\/0\/it\/Avextra-supporta-in-Italia-uno-studio-clinico-di-fase-II-sulla-cannabis-terapeutica-nelle-malattie-neurodegenerative.html\">Ulteriori informazioni<\/a><\/em><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Erster Patient in randomisierte, placebokontrollierte Studie aufgenommen Bensheim, 24. Oktober 2025 \u2013&nbsp;Neurodegenerative Erkrankungen geh\u00f6ren zu den gr\u00f6\u00dften medizinischen Herausforderungen unserer Zeit. In Deutschland leben derzeit rund 1,8 Millionen Menschen mit Demenz, eine Zahl, die aufgrund des demografischen Wandels in den kommenden Jahrzehnten voraussichtlich auf bis zu 2,7 Millionen im Jahr 2050 ansteigen wird. Die steigende [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5137,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"einzelbeitrag-ohne-bild","format":"standard","meta":{"inline_featured_image":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[8,9],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avextra.com\/it\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"og:description\" content=\"Erster Patient in randomisierte, placebokontrollierte Studie aufgenommen Bensheim, 24. Oktober 2025 \u2013&nbsp;Neurodegenerative Erkrankungen geh\u00f6ren zu den gr\u00f6\u00dften medizinischen Herausforderungen unserer Zeit. In Deutschland leben derzeit rund 1,8 Millionen Menschen mit Demenz, eine Zahl, die aufgrund des demografischen Wandels in den kommenden Jahrzehnten voraussichtlich auf bis zu 2,7 Millionen im Jahr 2050 ansteigen wird. Die steigende [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avextra.com\/it\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\" \/>\n<meta property=\"og:site_name\" content=\"Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T11:02:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-24T11:13:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"428\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MHorn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"MHorn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\"},\"author\":{\"name\":\"MHorn\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43\"},\"headline\":\"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien\",\"datePublished\":\"2025-10-24T11:02:40+00:00\",\"dateModified\":\"2025-10-24T11:13:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg\",\"articleSection\":[\"deutsch\",\"english\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\",\"url\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\",\"name\":\"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg\",\"datePublished\":\"2025-10-24T11:02:40+00:00\",\"dateModified\":\"2025-10-24T11:13:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg\",\"width\":640,\"height\":428},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/avextra.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/avextra.com\/#website\",\"url\":\"https:\/\/avextra.com\/\",\"name\":\"Cannabisbasierte Arzneimittel von Avextra\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/avextra.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/avextra.com\/#organization\",\"name\":\"Avextra Pharma GmbH\",\"url\":\"https:\/\/avextra.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"caption\":\"Avextra Pharma GmbH\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/avextra-ag\/\",\"https:\/\/www.xing.com\/pages\/avextra\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43\",\"name\":\"MHorn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g\",\"caption\":\"MHorn\"},\"sameAs\":[\"https:\/\/dev.studio-horn.de\/staging\/avextra\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avextra.com\/it\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/","og_locale":"it_IT","og_type":"article","og_title":"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra","og_description":"Erster Patient in randomisierte, placebokontrollierte Studie aufgenommen Bensheim, 24. Oktober 2025 \u2013&nbsp;Neurodegenerative Erkrankungen geh\u00f6ren zu den gr\u00f6\u00dften medizinischen Herausforderungen unserer Zeit. In Deutschland leben derzeit rund 1,8 Millionen Menschen mit Demenz, eine Zahl, die aufgrund des demografischen Wandels in den kommenden Jahrzehnten voraussichtlich auf bis zu 2,7 Millionen im Jahr 2050 ansteigen wird. Die steigende [&hellip;]","og_url":"https:\/\/avextra.com\/it\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/","og_site_name":"Cannabisbasierte Arzneimittel von Avextra","article_published_time":"2025-10-24T11:02:40+00:00","article_modified_time":"2025-10-24T11:13:13+00:00","og_image":[{"width":640,"height":428,"url":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg","type":"image\/jpeg"}],"author":"MHorn","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"MHorn","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#article","isPartOf":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/"},"author":{"name":"MHorn","@id":"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43"},"headline":"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien","datePublished":"2025-10-24T11:02:40+00:00","dateModified":"2025-10-24T11:13:13+00:00","mainEntityOfPage":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/"},"wordCount":534,"publisher":{"@id":"https:\/\/avextra.com\/#organization"},"image":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg","articleSection":["deutsch","english"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/","url":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/","name":"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien - Cannabisbasierte Arzneimittel von Avextra","isPartOf":{"@id":"https:\/\/avextra.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage"},"image":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg","datePublished":"2025-10-24T11:02:40+00:00","dateModified":"2025-10-24T11:13:13+00:00","breadcrumb":{"@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#primaryimage","url":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024.jpeg","width":640,"height":428},{"@type":"BreadcrumbList","@id":"https:\/\/avextra.com\/2025\/10\/avextra-unterstuetzt-klinische-phase-ii-studie-zum-therapeutischen-einsatz-von-cannabis-basierten-arzneimitteln-bei-neurodegenerativen-erkrankungen-in-italien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/avextra.com\/"},{"@type":"ListItem","position":2,"name":"Avextra unterst\u00fctzt klinische Phase-II-Studie zum therapeutischen Einsatz von Cannabis-basierten Arzneimitteln bei neurodegenerativen Erkrankungen in Italien"}]},{"@type":"WebSite","@id":"https:\/\/avextra.com\/#website","url":"https:\/\/avextra.com\/","name":"Cannabisbasierte Arzneimittel von Avextra","description":"","publisher":{"@id":"https:\/\/avextra.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avextra.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/avextra.com\/#organization","name":"Avextra Pharma GmbH","url":"https:\/\/avextra.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/","url":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","caption":"Avextra Pharma GmbH"},"image":{"@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/avextra-ag\/","https:\/\/www.xing.com\/pages\/avextra"]},{"@type":"Person","@id":"https:\/\/avextra.com\/#\/schema\/person\/7006cb73df866f43e6989b07577ecc43","name":"MHorn","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/446d07f04c2eb204a64dbbc0313e10c7?s=96&d=mm&r=g","caption":"MHorn"},"sameAs":["https:\/\/dev.studio-horn.de\/staging\/avextra"]}]}},"author_meta":{"display_name":"MHorn","author_link":"https:\/\/avextra.com\/it\/author\/mhorn\/"},"featured_img":"https:\/\/avextra.com\/wp-content\/uploads\/2025\/10\/Neurobis_PM-Vorschaubild_2048x1370_PM-251024-300x201.jpeg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/avextra.com\/it\/category\/deutsch\/\" class=\"advgb-post-tax-term\">deutsch<\/a>","<a href=\"https:\/\/avextra.com\/it\/category\/english\/\" class=\"advgb-post-tax-term\">english<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">deutsch<\/span>","<span class=\"advgb-post-tax-term\">english<\/span>"]}},"comment_count":0,"relative_dates":{"created":"Pubblicato 6 mesi fa","modified":"Aggiornato 6 mesi fa"},"absolute_dates":{"created":"Pubblicato il 24. Ottobre 2025","modified":"Aggiornato il 24. Ottobre 2025"},"absolute_dates_time":{"created":"Pubblicato il 24. Ottobre 2025 13:02","modified":"Aggiornato il 24. Ottobre 2025 13:13"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/5128"}],"collection":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/comments?post=5128"}],"version-history":[{"count":9,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/5128\/revisions"}],"predecessor-version":[{"id":5140,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/5128\/revisions\/5140"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/media\/5137"}],"wp:attachment":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/media?parent=5128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/categories?post=5128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/tags?post=5128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}